Concepedia

Author

D. R. A. Uges

University of Groningen

Also Known As

D R A Uges, D R Uges, D RA Uges, D UGES, D. R. A. Uges, D. R.A. Uges, D.R. A. Uges, D.R.A. Uges, DR Uges, Donald R. A. Uges

33

Publications

1.4K

Citations

17

H-Index

61

Concepts

All Affiliations

University of GroningenUniversity Medical Center GroningenNetherlands Forensic InstitutePharmo InstituteErasmus MC
DR

About

D. R. A. Uges is an author at University of Groningen specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

12

532

2

Health Sciences

2

2

159

3

Engineering

1

1

438

4

Public Health

1

1

76

5

Biochemistry

1

1

17

D. R. A. Uges

×

17

Publications

1.2K

Citations

15

H-Index

YearCitations

Electrochemical and surface characterization of a nickel–titanium alloy

Dirk Jan Wever, Albert G. Veldhuizen, J. de Vries,

Biomaterials

1998

438

Quantitative analysis of 33 benzodiazepines, metabolites and benzodiazepine-like substances in whole blood by liquid chromatography?(tandem) mass spectrometry

B. E. Smink, J BRANDSMA, Albert Dijkhuizen,

Journal of Chromatography B

2004

96

Influence of functional polymorphisms of the gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia

Sabine Plasschaert, Ellis Groninger, Marike Boezen,

Clinical Pharmacology & Therapeutics

2004

91

Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience

Arianna D. Pranger, Richard van Altena, Rob E. Aarnoutse,

European Respiratory Journal

2011

83

Drug use and the severity of a traffic accident

B. E. Smink, B. Ruiter, Klaas J. Lusthof,

Accident Analysis & Prevention

2005

76

Quantitative analysis of 33 benzodiazepines, metabolites and benzodiazepine-like substances in whole blood by liquid chromatography–(tandem) mass spectrometry

B. E. Smink, J BRANDSMA, Albert Dijkhuizen,

Journal of Chromatography B

2004

58

High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors.

P O Mulder, D.Th. Sleijfer, P.H.B. Willemse,

PubMed

1989

56

Phase II Study of Oral Platinum Drug JM216 as First-Line Treatment in Patients With Small-Cell Lung Cancer

Eelco Fokkema, Harry J.M. Groen, Jean Bauer,

Journal of Clinical Oncology

1999

51

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors

Jourik A. Gietema, Ronald Hoekstra, Filip De Vos,

Annals of Oncology

2006

48

Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combination

Ronald Hoekstra, Filip De Vos, Ferry A.L.M. Eskens,

European Journal of Cancer

2006

43

Page 1